N-desmethyl Netupitant, a metabolite of Netupitant, plays a significant role in the field of medical therapeutics, particularly in the management of nausea and vomiting associated with chemotherapy. It is integral to the effectiveness of antiemetic regimens, where it contributes to the prevention of acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV). The metabolite enhances the therapeutic profile by ensuring sustained activity, thereby improving patient comfort and adherence to cancer treatment protocols. Its application is crucial in combination therapies, often paired with other agents to optimize control over emetic episodes, thus supporting the overall efficacy of cancer care strategies.